Serum Institute writes to PMO seeking reforms in drug regulations for non-COVID vaccines

Manufacture and stockpile of Covishield doses during the clinical trial helped bring the vaccine out quicker, protecting millions of lives, the letter said.

Press Trust of India March 05, 2021 10:36:17 IST
Serum Institute writes to PMO seeking reforms in drug regulations for non-COVID vaccines

Stock boxes of Covishield vaccine vials. Image: AP

The world's largest vaccine manufacturer by volume, Serum Institute of India, has written to the Prime Minister's Office proposing reforms in the existing drug regulatory system, including allowing manufacturing and stockpiling of non-COVID vaccines while undergoing clinical trial. In the letter, Prakash Kumar Singh, the Director of Government and Regulatory Affairs at the Pune-based Serum Institute of India (SII) referred to the Health Ministry's 18 May 2020 gazette notification, saying it allowed manufacturing and stockpiling of COVID-19 vaccine under clinical trial for marketing authorization for sale or distribution.

"Because of this rule, it became possible for us to manufacture and stockpile the COVID-19 vaccine during the clinical trial and we could make the vaccine available in such a short span of time to protect millions of lives," he said in the letter dated 2 March.

By the end of 2020, SII has already produced around 50 million dosages of the Oxford-AstraZeneca COVID-19 vaccine 'Covishield', even while it awaited the Drugs Controller General of India's (DCGI) nod for emergency use of its vaccine in the country. It got the nod in early January this year.

"In view of the successful result of this provision for COVID-19 vaccine, this provision should also be implemented for non- COVID-19 vaccines," Singh said.

In the letter to the PMO, he also sought permission to use the remaining quantities of batches of COVID and non-COVID vaccines for commercial purpose which have been used in a clinical trial. In this context, he said the Health Ministry had issued draft rules dated 12 April 2018, to allow the remaining quantities of batches of vaccines which have been used in a clinical trial for commercial use after the grant of permission in Form 46 (now it is Form CT-23) and manufacturing licence in Form 28D.

Updated Date:

also read

US evasive on allowing export of critical COVID-19 vaccine raw materials to India
World

US evasive on allowing export of critical COVID-19 vaccine raw materials to India

The White House said that it would be difficult to export the critical raw materials mainly due to an Act that forces American companies to prioritise domestic consumption

Six states say COVID-19 vaccine stocks petering out; Maharashtra laments getting 7.5 lakh doses as UP gets 48 lakh
India

Six states say COVID-19 vaccine stocks petering out; Maharashtra laments getting 7.5 lakh doses as UP gets 48 lakh

An analysis of available data suggests that while India is administering 34-35 lakh doses daily, its daily production capacity is no more than 26 lakh doses at present. And this is when SII is prioritising India's needs over its global obligations, as a stopgap measure

COVID-19 vaccine shortages hit poorer countries after India stops exporting jabs from Serum Institute
World

COVID-19 vaccine shortages hit poorer countries after India stops exporting jabs from Serum Institute

In the past two weeks, only 2 million doses were cleared for shipment to 92 countries through the COVAX programme, the same amount injected in Britain alone